NeuroSense Therapeutics Ltd.
Business
NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company developing treatments for neurodegenerative diseases including ALS, Alzheimer's disease, and Parkinson's disease. Its lead candidate, PrimeC, is a novel extended-release oral fixed-dose combination of ciprofloxacin and celecoxib designed to modulate multiple disease pathways. The company conducts preclinical and clinical research, with PrimeC having completed Phase 2b trials in ALS and Phase 2 trials in Alzheimer's disease, and plans a pivotal Phase 3 study in ALS. NeuroSense operates through contract manufacturers and relies on third-party vendors for drug manufacturing and supply.
Summary from 20-F filed 2026-03-31
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-11.13M |
| Total assets | $1.03M |
| Total liabilities | $2.59M |
| Stockholders' equity | $-1.56M |
| Operating cash flow | $-7.67M |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is NeuroSense Therapeutics Ltd.'s CIK number?
NeuroSense Therapeutics Ltd.'s SEC CIK number is 0001875091 (1875091). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find NeuroSense Therapeutics Ltd.'s SEC filings?
All of NeuroSense Therapeutics Ltd.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.